Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Introgen Therapeutics -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (192)	1/14/2005 3:02:49 PM
From: fred hayes	Read Replies (2) \| Respond to of 802

who owns peg-3?: Columbia University filed patent application July 20, 2000, but unable to confirm it was issued or that they still own it. Don't know if this helps. Not a real good searcher... 164.195.100.11@ISD%3E=20040512<=20040608+AND+ny.ASST.)+AND+university.ASNM.)&OS=isd/20040512->20040608+and+as/ny+and+an/university&RS=((ISD/20040512->20040608+AND+AS/ny)+AND+AN/university) Nucleic acids comprising regions of the rat PEG-3 promoter that display elevated expression in human cancer cells and uses thereof Abstract This invention provides an isolated nucleic acid comprising a PEG-3 promoter comprising the nucleotide sequence of -270 to +194 of FIG. 2. The invention also provides a method for identifying an agent that modulates PEG-3 promoter activity using a cell which comprises a PEG-3 promoter operatively linked to a reporter gene, wherein reduced reporter gene expression in the presence of the agent is indicative of an agent that inhibits PEG-3 promoter activity and wherein increased reporter gene expression in the presence of the agent is indicative of an agent that enhances PEG-3 promoter activity. The invention provides a method for treating cancer in a subject which comprises administering a nucleic acid comprising a PEG-3 promoter operatively linked to a gene-of-interest, wherein the gene-of-interest is selectively expressed in cancerous cells in the subject and such expression results in growth suppression or death of the cancerous cells. Inventors: Fisher; Paul B. (Scarsdale, NY); Su; Zao-Zhong (New York, NY) Assignee: The Trustees of Columbia University in the City of New York (New York, NY) Appl. No.: 621781 Filed: July 21, 2000 Current U.S. Class: 536/24.1; 435/320.1; 435/366; 435/455 Intern'l Class: C07H 021/04; C12N 015/00 Field of Search: 536/24.1 435/320.1,455,366